ANIP - ANI Pharma reaches a seven-month low on soft guidance for 2022

The shares of ANI Pharmaceuticals (ANIP -24.3%) have approached the lowest level since August after the maker of branded and generic medicines posted a lower than expected guidance for 2022. Net revenue for the quarter rose ~6% YoY to $60.9M as revenue from generic pharmaceuticals jumped ~8% YoY to $41.6M while revenue from branded pharmaceuticals slipped ~7% YoY to $14.7M. Meanwhile, GAAP net loss rose over six times from the prior-year quarter to $24.1M as SG&A expenses more than doubled to $30.7M. For the full year, the company reported $216.1M in net revenue with ~4% YoY growth. 2021 GAAP net loss rose ~89% YoY to $42.6M as SG&A expenses climbed ~30% YoY to $84.3M. The cash and equivalents stood at $100.3M at the year-end compared to $7.9M a year ago. Commenting on the company’s recent acquisition of Novitium Pharma, Chief Executive, Nikhil Lalwani, said: “Since deal closure, our integrated team has

For further details see:

ANI Pharma reaches a seven-month low on soft guidance for 2022